(2R)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane hydrate dihydrochloride

• ChemBase编号: 155275
• 分子式: C11H17Cl3N2O
• 平均质量: 299.62448
• 单一同位素质量: 298.04064621
• SMILES: c1cc(ncc1[C@H]1CC2CCC1N2)Cl.O.Cl.Cl
• Canonical SMILES: Clc1ccc(cn1)[C@H]1CC2NC1CC2.O.Cl.Cl
• InChI: InChI=1S/C11H13ClN2.2ClH.H2O/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8;;;/h1,4,6,8-10,14H,2-3,5H2;2*1H;1H2/t8?,9-,10?;;;/m1.../s1
• InChIKey: AXWYRFKDLRSESC-VAGRNHIFSA-N

名称和登记号

名称

• IUPAC标准名: (2R)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane hydrate dihydrochloride
• IUPAC传统名: (2R)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane hydrate dihydrochloride
• 别名: exo-(±)-2-(6-Chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane dihydrochloride hydrate; (±)-Epibatidine dihydrochloride hydrate

登记号

• PubChem SID: 162249413; 24894390
• PubChem CID: 16219300

理论计算性质

• 质子受体: 2
• 质子供体: 1
• LogD (pH = 5.5): -1.3915857
• LogD (pH = 7.4): -1.0436354
• Log P: 1.8435768
• 摩尔折射率: 57.3916 cm^3
• 极化性: 22.39249 Å^3
• 极化表面积: 24.92 Å^2
• 可自由旋转的化学键: 1
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO: >4 mg/mL; methanol: soluble4 mg/mL
• 外观: off-white powder

安全信息

• 欧盟危险性物质标志: 剧毒(Highly toxic) (T+)
• 联合国危险货物编号: 2811
• 德国WGK号: 3
• 联合国危险货物等级: 6.1
• 联合国危险货物包装类别(PG): 1
• 危险公开号: 27/28
• 安全公开号: 28-36/37-45
• GHS危险品标识: GHS06
• GHS警示词: Danger
• GHS危险声明: H300-H310
• GHS警示性声明: P264-P280-P301 + P310-P302 + P350-P310
• 个人保护装置: Eyeshields, Faceshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges
• RID/ADR: UN 2811 6.1/PG 1

产品相关信息

• 纯度: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C11H13ClN2 · 2HCl · xH2O

详细说明

Sigma Aldrich - E1145

Biochem/physiol Actions
The activity of epibatidine at neuronal and neuromuscular nicotinic acetylcholine receptors was compared with the activity of nicotine and suxamethonium. Activation of ganglionic nicotinic receptors by epibatidine was shown in the guinea-pig ileum (contraction mediated by the cholinergic neurons of the ileum) and in pithed and atropinized rats (rise in blood pressure). Epibatidine also activated nicotinic receptors at the peripheral terminals of afferent C-fibres (rabbit ear) and in the brain (antidiuresis in rats). The agonistic effects of epibatidine were followed by long-lasting receptor desensitization. No antinociceptive effect of epibatidine was seen in rats at a dose free of motor impairment. On muscle end plate nicotinic receptors of the rat diaphragm (not responding to depolarizing agents by contraction), epibatidine was equipotent with suxamethonium in causing neuromuscular inhibition. On an extraocular muscle of the rabbit (responding to depolarizing agents by contraction) epibatidine in vitro and in situ caused a contraction at a 100-fold lower dose than suxamethonium. The Straub tail reaction in mice to epibatidine could be attributed to the sustained stimulation of motor end plate receptors of the "slow contracting" type of muscle fibres by epibatidine. Epibatidine was the most potent agonist on all neuronal and neuromuscular nicotinic receptors examined.